Press "Enter" to skip to content

Indivior To Pay Over 100% Premium To Buy Opioid Focused Player Opiant Pharmaceuticals

  • Indivior PLC INVVY has agreed to acquire Opiant Pharmaceuticals Inc OPNT for $20.00 per share in cash, plus contingent value rights (CVRs) of up to $8.00 per share
  • Achievement of the CVR payments, if any, is based on attaining certain revenue thresholds for OPNT003, nasal nalmefene, and Opiant’s investigational treatment for opioid overdose.
  • Completion of rolling New Drug Application (NDA) submission for OPNT003 is on track for Q4 2022.
  • The upfront payment of $20.00 per share represents a premium of approximately 111% to Opiant’s closing share price on November 11. 
  • Inclusive of each CVR payment, the total potential transaction value represents a premium of up to 195%.
  • Pending approvals, the parties anticipate completing the transaction in the first quarter of 2023.
  • Opiant entered a settlement with Emergent Biosolutions Inc EBS, resolving a legal dispute over its royalty obligations to Opiant for NARCAN Nasal Spray. 
  • Under the settlement, EBS will make a one-time cash payment of $25 million to Opiant to terminate its license agreement with Opiant.
  • Related: Opiant Pharma Secures Additional BARDA Funding For Opioid Overdose Treatment.
  • For Q3, Opiant recorded $0.2 million of revenue, compared to $16.3 million a year ago, primarily from a contract with the Biomedical Advanced Research and Development Authority. Opiant recorded no royalty revenue from its license agreement with EBS.
  • Opiant had approximately $35.4 million in cash and cash equivalents as of September 30.
  • Price Action: OPNT shares are up 116.80% at $20.60 during the premarket session on the last check Monday.

This post was originally published on this site

Be First to Comment

Leave a Reply

Your email address will not be published.